 The FDA has instituted a partial clinical hold on Aprea Therapeutics Incs NASDAQ: APRE clinical trials of eprenetapopt APR-246 combined with azacitidine in its myeloid malignancy programs. Approximately 20 patients currently receiving eprenetapopt in combination with azacitidine in the Companys myeloid malignancy programs, including the MDS, AML, and post-transplant maintenance trials, all of which have completed enrollment. 